Exchange Traded Concepts LLC Buys 28,569 Shares of Medtronic PLC $MDT

Exchange Traded Concepts LLC lifted its stake in shares of Medtronic PLC (NYSE:MDT) by 29.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 124,000 shares of the medical technology company’s stock after acquiring an additional 28,569 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Medtronic were worth $11,911,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MDT. Delos Wealth Advisors LLC bought a new position in shares of Medtronic in the second quarter worth approximately $27,000. Corundum Trust Company INC bought a new stake in shares of Medtronic during the 3rd quarter valued at $27,000. Valley Wealth Managers Inc. purchased a new position in shares of Medtronic during the 3rd quarter valued at $29,000. Board of the Pension Protection Fund purchased a new position in shares of Medtronic during the 4th quarter valued at $29,000. Finally, GoalVest Advisory LLC bought a new position in Medtronic in the 4th quarter worth $29,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA clearance expands addressable market for Stealth AXiS — The U.S. FDA cleared Medtronic’s Stealth AXiS surgical system for cranial and ENT procedures, adding to the spine clearance received in February. The broader indication increases the platform’s market opportunity for navigation + robotics in higher‑value neurosurgical/ENT cases, supporting future procedure volume and device sales. Medtronic gets US FDA nod to use surgical system in cranial, ENT surgeries
• Positive Sentiment: Distribution deal adds a minimally invasive pain product to the portfolio — Medtronic expanded distribution with Merit Medical for the ViaVerte™ basivertebral nerve ablation (BVNA) system, a minimally invasive, implant‑free therapy for chronic low back pain. This is a commercially relevant, non‑capital product that could contribute recurring revenue and broaden Medtronic’s spine/pain offerings. Medtronic (MDT) Expands Partnership with Merit Medical for ViaVerte System
• Positive Sentiment: Analyst reaffirmation with a high price target — Needham reiterated a Buy rating and $120 price target on MDT, signaling continued analyst confidence in Medtronic’s multi‑year growth thesis (including tuck‑ins, robotics, and margin improvement). That target implies substantial upside from current levels and can support investor sentiment. Needham Reiterates Buy Rating on Medtronic
• Positive Sentiment: Strategic spin‑off plan remains a potential value catalyst — Coverage highlights Medtronic’s planned spin‑off of its high‑growth diabetes unit later this year. A diabetes spin‑off could unlock value for the parent (focused on cardiovascular, robotics, and other higher‑margin hospital businesses) and make both entities more strategically coherent. 5 Spin-Off Stocks That Could Reward Patient Investors in 2026
• Neutral Sentiment: Investor writeups argue the company is set for faster growth — Recent commentary (e.g., Seeking Alpha’s “Time For A Growth Spurt”) lays out a bullish case around robotics, procedure growth, and margin leverage; these are thematic/analytical pieces rather than direct catalysts. Impact timing is uncertain. Medtronic: Time For A Growth Spurt
• Negative Sentiment: Near‑term technicals and volume suggest selling pressure — MDT is trading below its 50‑ and 200‑day moving averages with intraday volume above average, a setup that can keep the stock under pressure despite positive fundamental news until technicals stabilize.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on MDT shares. Needham & Company LLC reiterated a “buy” rating and issued a $120.00 price target on shares of Medtronic in a research note on Thursday. JPMorgan Chase & Co. lowered their price objective on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. CICC Research initiated coverage on Medtronic in a research note on Friday, January 30th. They issued an “outperform” rating for the company. Barclays reiterated an “overweight” rating and set a $118.00 target price on shares of Medtronic in a research report on Wednesday, February 18th. Finally, Wells Fargo & Company initiated coverage on Medtronic in a report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, Medtronic has an average rating of “Moderate Buy” and an average price target of $110.74.

Medtronic Stock Performance

Shares of NYSE MDT opened at $87.20 on Friday. The company has a market cap of $111.96 billion, a P/E ratio of 24.29, a P/E/G ratio of 2.24 and a beta of 0.71. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The firm’s fifty day moving average is $95.80 and its two-hundred day moving average is $96.49.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio is presently 79.11%.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).